not sure about the “isn’t enough to make money” point…. Doesn’t CarT treatment costs run into hundreds of k - which suggests a few hundred patients receiving this treatment if available would be an extremely healthy level of (yearly) returns - loads of assumptions naturally, but I certainly don’t think they’re pursuing a commercial white elephant re GBM?
not sure about the “isn’t enough to make money” point…. Doesn’t...
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $17.98M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $28.15K | 1.320M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 938219 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 116461 | 2 |
View Market Depth
| Last trade - 15.50pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.2¢ |
Change
-0.001 ( 2.22 %) |
||||
| Open | High | Low | Volume | ||
| 2.2¢ | 2.2¢ | 2.1¢ | 798132 | ||
| Last updated 14.32pm 17/05/2024 ? | |||||
| CHM (ASX) Chart |